These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19647313)

  • 1. Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization.
    Oh EJ; Park K; Choi JS; Joo CK; Hahn SK
    Biomaterials; 2009 Oct; 30(30):6026-34. PubMed ID: 19647313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy.
    Oh EJ; Choi JS; Kim H; Joo CK; Hahn SK
    Biomaterials; 2011 Apr; 32(11):3115-23. PubMed ID: 21277020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization.
    Kim H; Choi JS; Kim KS; Yang JA; Joo CK; Hahn SK
    Acta Biomater; 2012 Nov; 8(11):3932-40. PubMed ID: 22824530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-photon microscopy of a Flt1 peptide-hyaluronate conjugate.
    Beack S; Choi JS; Lee JH; Kim H; Kim KH; Joo CK; Hahn SK
    Nanomedicine (Lond); 2015; 10(15):2315-24. PubMed ID: 26228271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioimaging and pulmonary applications of self-assembled Flt1 peptide-hyaluronic acid conjugate nanoparticles.
    Kim H; Park HT; Tae YM; Kong WH; Sung DK; Hwang BW; Kim KS; Kim YK; Hahn SK
    Biomaterials; 2013 Nov; 34(33):8478-90. PubMed ID: 23932502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo.
    Bian F; Zhang MC; Zhu Y
    Ophthalmologica; 2008; 222(3):178-86. PubMed ID: 18497527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction of hyaluronic acid-peptide conjugate for formyl peptide receptor like 1 receptor.
    Oh EJ; Kim JW; Kong JH; Ryu SH; Hahn SK
    Bioconjug Chem; 2008 Dec; 19(12):2401-8. PubMed ID: 19007292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
    Jiang G; Park K; Kim J; Kim KS; Hahn SK
    Mol Pharm; 2009; 6(3):727-37. PubMed ID: 19178144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Flt1 peptide and cyanine-conjugated gold nanoparticles for the concurrent antiangiogenic and endothelial cell proton treatment.
    Seo SJ; Lee SH; Kim KH; Kim JK
    J Biomed Mater Res B Appl Biomater; 2019 May; 107(4):1272-1283. PubMed ID: 30199611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.
    Hosseini H; Nejabat M
    Med Hypotheses; 2007; 68(4):799-801. PubMed ID: 17107753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide.
    Patel NS; Quadros A; Brem S; Wotoczek-Obadia M; Mathura VS; Laporte V; Mullan M; Paris D
    Amyloid; 2008 Mar; 15(1):5-19. PubMed ID: 18266117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Endothelial Growth Factor Receptor 1 Targeting Fusion Polypeptides with Stimuli-Responsiveness for Anti-angiogenesis.
    Kang MJ; Roh KH; Lee JS; Lee JH; Park S; Lim DW
    ACS Appl Mater Interfaces; 2023 Jul; 15(27):32201-32214. PubMed ID: 37384534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target specific hyaluronic acid-interferon alpha conjugate for the treatment of hepatitis C virus infection.
    Yang JA; Park K; Jung H; Kim H; Hong SW; Yoon SK; Hahn SK
    Biomaterials; 2011 Nov; 32(33):8722-9. PubMed ID: 21872329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.
    Kong JH; Oh EJ; Chae SY; Lee KC; Hahn SK
    Biomaterials; 2010 May; 31(14):4121-8. PubMed ID: 20149450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained release formulation of erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition.
    Hahn SK; Oh EJ; Miyamoto H; Shimobouji T
    Int J Pharm; 2006 Sep; 322(1-2):44-51. PubMed ID: 16781096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid-endostatin2-alft1 (HA-ES2-AF) nanoparticle-like conjugate for the target treatment of diseases.
    Sun F; Yu Y; Yang Z; Wang Z; Li Y; Wang F; Tan H
    J Control Release; 2018 Oct; 288():1-13. PubMed ID: 30170067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1.
    Al-Mahmood S; Colin S; Farhat N; Thorin E; Steverlynck C; Chemtob S
    J Pharmacol Exp Ther; 2009 May; 329(2):496-504. PubMed ID: 19208899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity.
    Lee H; Lee K; Park TG
    Bioconjug Chem; 2008 Jun; 19(6):1319-25. PubMed ID: 18481885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of corneal neovascularization with propolis extract.
    Keshavarz M; Mostafaie A; Mansouri K; Shakiba Y; Motlagh HR
    Arch Med Res; 2009 Jan; 40(1):59-61. PubMed ID: 19064129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.